drugset / Trial / NCT03108469
Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine
Phase 2
Completed
30 enrolled
Smith, Timothy R., M.D.
Clinvest Research, LLC · collabIonis Pharmaceuticals · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and changes in the number of migraine and headache days with repeated subcutaneous administration of IONIS-PKKRx (ISIS 546254) or placebo in subjects with chronic migraine.
Timeline
- Start
- 2017-08-01
- Primary completion
- 2019-04-26
- Completion
- 2019-04-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | IONIS-PKKRx | Unknown | 200 mg | Subcutaneous |